{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:07:29Z","timestamp":1791061649332,"version":"4.1.0"},"reference-count":27,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,11,17]]},"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The human papillomavirus (HPV) immunisation programme in England was introduced in 2008. Monitoring changes in type-specific HPV prevalence allows assessment of the population impact of this vaccination programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Residual vulva-vaginal swab specimens were collected from young sexually active women (aged 16\u201324\u2005years) attending for chlamydia screening across England. Specimens were collected between 2010 and 2013 for type-specific HPV-DNA testing. HPV prevalence was compared to a similar survey conducted in 2008 prior to the introduction of HPV vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 7321 specimens collected in the postvaccination period, and 2354 specimens from the prevaccination period were included in this analysis. Among the individuals aged 16\u201318\u2005years, with an estimated vaccination coverage of 67%, the prevalence of HPV16\/18 infection decreased from 17.6% in 2008 to 6.1% in the postvaccination period. Within the postvaccination period, there was a trend towards lower HPV16\/18 prevalence with higher vaccination coverage and increasing time since vaccine introduction from 8.5% in the period 2\u20133\u2005years postvaccination to 4.0% in the period 4\u20135\u2005years postvaccination. The prevalence of HPV31 reduced from 3.7% in the prevaccination period to 0.9% after vaccine introduction, although this no longer reached statistical significance after additional consideration of the uncertainty due to the assay change. Smaller reductions were seen in the individuals aged 19\u201321\u2005years with lower estimated vaccination coverage, but there was no evidence of a reduction in the older unvaccinated women. Some overall increase in non-vaccine types was seen in the youngest age groups (ORs (95% CI); 1.3 (1.0 to 1.7) and 1.5 (1.1 to 2.0) for individuals aged 16\u201318 and 19\u201321\u2005years, respectively, when adjusted for known population changes and the change in assay) although this should be interpreted with caution given the potential unmasking effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate a reduction in the HPV vaccine types in the age group with the highest HPV vaccination coverage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009915","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:08:39Z","timestamp":1455235719000},"page":"e009915","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Continuing reductions in HPV 16\/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study"],"prefix":"10.1136","volume":"6","author":[{"given":"David","family":"Mesher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Panwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"2024051515044139000_6.2.e009915.1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"2024051515044139000_6.2.e009915.2","unstructured":"IARC Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: World Health Organisation International Agency for Research on Cancer, 2012."},{"key":"2024051515044139000_6.2.e009915.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25396"},{"key":"2024051515044139000_6.2.e009915.4","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202681"},{"key":"2024051515044139000_6.2.e009915.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.026"},{"key":"2024051515044139000_6.2.e009915.6","unstructured":"Cervical Cancer Action. Global Progress in HPV Vaccination. http:\/\/www.cervicalcanceraction.org\/comments\/comments3.php (accessed Nov 2014)."},{"key":"2024051515044139000_6.2.e009915.7","unstructured":"Department of Health, Health Protection Agency. Annual HPV vaccine uptake in England: 2010\/11. http:\/\/webarchive.nationalarchives.gov.uk\/20130107105354\/https:\/\/www.wp.dh.gov.uk\/immunisation\/files\/2012\/03\/120319_HPV_UptakeReport2010\u201311-revised_acc.pdf (accessed Apr 2015)."},{"key":"2024051515044139000_6.2.e009915.8","unstructured":"Department of Health, Health Protection Agency. Annual HPV vaccine uptake in England: 2011\/12. http:\/\/webarchive.nationalarchives.gov.uk\/20130123170526\/http:\/\/immunisation.dh.gov.uk\/ann-hpv-vac-cover-england-201112\/ (accessed Apr 2015)."},{"key":"2024051515044139000_6.2.e009915.9","unstructured":"Public Health England. Annual HPV vaccine coverage in England: 2012\/13. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/266190\/HPV_AnnualDataTable2012_13_SHA_acc2.pdf (accessed Apr 2015)."},{"key":"2024051515044139000_6.2.e009915.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.039"},{"key":"2024051515044139000_6.2.e009915.11","unstructured":"Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008\/09 to 2013\/14: A review of the full six years of the three-dose schedule. https:\/\/www gov uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/412264\/HPV_Vaccine_Coverage_in_England_200809_to_201314 pdf 2015 (accessed Oct 2015)."},{"key":"2024051515044139000_6.2.e009915.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.042"},{"key":"2024051515044139000_6.2.e009915.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.085"},{"key":"2024051515044139000_6.2.e009915.14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis590"},{"key":"2024051515044139000_6.2.e009915.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.057"},{"key":"2024051515044139000_6.2.e009915.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3587"},{"key":"2024051515044139000_6.2.e009915.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit192"},{"key":"2024051515044139000_6.2.e009915.18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.198"},{"key":"2024051515044139000_6.2.e009915.19","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0687"},{"key":"2024051515044139000_6.2.e009915.20","doi-asserted-by":"publisher","DOI":"10.1086\/597307"},{"key":"2024051515044139000_6.2.e009915.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"2024051515044139000_6.2.e009915.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"2024051515044139000_6.2.e009915.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.006"},{"key":"2024051515044139000_6.2.e009915.24","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22167"},{"key":"2024051515044139000_6.2.e009915.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"2024051515044139000_6.2.e009915.26","unstructured":"Department of Health, Health Protection Agency. Annual HPV vaccine coverage in England in 2009\/2010. https:\/\/www.gov.uk\/government\/publications\/annual-hpv-vaccine-coverage-in-england-in-2009\u20132010 (access Apr 2015)."},{"key":"2024051515044139000_6.2.e009915.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71073-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T18:08:40Z","timestamp":1715796520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,11]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1136\/bmjopen-2015-009915"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009915","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726141932.793529264","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}